What is the recommended management and follow-up for central nervous system tuberculosis?

Management and Follow-Up of Central Nervous System Tuberculosis

Initial Treatment Regimen

For CNS tuberculosis, initiate a 12-month regimen consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol (as the fourth drug in adults) for the first 2 months, followed by rifampicin and isoniazid for the remaining 10 months. 1, 2, 3

Drug Dosing for Adults

• Rifampicin: 450 mg daily (≤50 kg) or 600 mg daily (>50 kg) 2
• Isoniazid: 300 mg daily 2
• Pyrazinamide: 1.5 g daily (≤50 kg) or 2.0 g daily (>50 kg) 2
• Ethambutol: 15 mg/kg daily 2

The standard 6-month regimen used for pulmonary tuberculosis is insufficient for CNS involvement and must not be used. 1, 2

Specific CNS Presentations

Tuberculous Meningitis:

• Use the same 4-drug intensive phase for 2 months, but extend total treatment to 12 months minimum 1, 3
• Streptomycin, ethambutol, or ethionamide can serve as the fourth drug, though ethambutol is preferred in adults who can report visual symptoms 1, 2
• In unconscious patients (stage III meningitis), use ethambutol with caution since visual acuity cannot be monitored 1

Isolated CNS Tuberculoma (without meningitis):

• Apply the same 12-month regimen as above 1, 2
• Do not use corticosteroids routinely for isolated tuberculomas 2

Disseminated/Miliary TB with CNS involvement:

• Perform lumbar puncture in all miliary TB cases to detect meningeal involvement, as this determines treatment duration 1
• If meningitis is confirmed, treat for 12 months; if absent, 6 months may suffice for non-CNS sites 1

Adjunctive Corticosteroid Therapy

For tuberculous meningitis, prescribe adjunctive corticosteroids (dexamethasone or prednisolone) tapered over 6-8 weeks regardless of disease severity. 1, 3 This recommendation is supported by moderate-certainty evidence showing mortality benefit. 1

• Corticosteroids are not recommended for isolated tuberculomas without meningitis 2
• For severe respiratory failure or adrenal insufficiency in disseminated TB, corticosteroids may be indicated 1

Pre-Treatment Screening and Baseline Monitoring

Before initiating therapy, obtain:

• Visual acuity testing (Snellen chart) for all patients who will receive ethambutol; document that the patient understands to stop the drug immediately if visual changes occur 1, 2
• Renal function tests before using streptomycin or ethambutol; avoid these drugs in renal failure or monitor serum concentrations with dose reduction 1, 2
• Baseline liver function tests (AST/ALT, bilirubin) for all patients 1, 2
• HIV testing in all patients, as co-infection complicates management and affects prognosis 3
• Lumbar puncture in all suspected CNS TB cases to confirm diagnosis and exclude concurrent meningitis in tuberculoma patients 1, 2, 3

Ongoing Monitoring During Treatment

Liver Function Monitoring

For patients with chronic liver disease:

• Monitor liver function weekly for 2 weeks, then every 2 weeks for the first 2 months 1, 2

For patients with normal baseline liver function:

• Routine monitoring is not required 1, 2
• Repeat liver function tests only if symptoms develop (fever, malaise, vomiting, jaundice, unexplained deterioration) 1, 2

Drug discontinuation thresholds:

• Stop rifampicin, isoniazid, and pyrazinamide if AST/ALT rises to ≥5 times normal or if bilirubin rises significantly 1, 2
• If the patient is well and non-infectious, withhold treatment until liver function normalizes 1
• If the patient is unwell or smear-positive, use streptomycin and ethambutol (with appropriate monitoring) until liver function recovers 1

Visual Monitoring for Ethambutol

• Perform monthly color discrimination tests and inquire about visual disturbances 1
• Patients must be able to report visual symptoms; in young children or those with communication barriers, educate family members 1

Microbiological and Clinical Monitoring

• Lumbar puncture: Consider serial lumbar punctures to monitor CSF cell count, glucose, and protein, especially early in treatment 1
• Sputum cultures (if pulmonary involvement): Obtain monthly until two consecutive specimens are negative 1
• Weight monitoring: Assess monthly to adjust medication doses as needed 1
• Symptom assessment: Monitor for improvement in TB symptoms (cough, fever, night sweats) and development of adverse drug effects 1

Management of Drug Resistance

• Obtain drug susceptibility testing for isoniazid, rifampicin, ethambutol, and pyrazinamide at baseline 1
• Use rapid molecular testing (e.g., GeneXpert) on at least one baseline specimen 1
• If drug resistance is identified, refer immediately to specialists experienced in multidrug-resistant TB 2, 3
• For MDR/RR-TB with CNS involvement, individualized longer regimens are required, incorporating Group A drugs (fluoroquinolones, bedaquiline, linezolid) 1

Special Populations

HIV Co-Infection

• Manage in collaboration with HIV specialists or within combined TB-HIV units 3
• Rifampicin induces CYP3A enzymes, markedly reducing protease inhibitor levels 1, 2
• Three management options exist:
  1. Preferred: Discontinue protease inhibitors and use alternative antiretrovirals until TB treatment completes 1
  2. Omit rifampicin and extend TB treatment to 18 months 1
  3. Use indinavir with rifabutin (reduced dose) substituted for rifampicin 1

Children

• Manage with a pediatrician experienced in pediatric TB or with input from pediatric infectious disease specialists 3
• Use the same 12-month regimen; consider ethionamide or an aminoglycoside instead of ethambutol as the fourth drug in young children who cannot report visual symptoms 1

Common Pitfalls and Caveats

• Do not delay treatment waiting for microbiological confirmation; CNS TB is a medical emergency, and empiric therapy should start immediately when clinically suspected 3
• Do not use the 6-month regimen for any form of CNS TB; this is a critical error that leads to treatment failure 1, 2
• Do not omit pyrazinamide from the intensive phase, as it penetrates the blood-brain barrier well and is essential for CNS TB 1, 4
• Do not routinely give corticosteroids for isolated tuberculomas; reserve them for meningitis 2
• Do not miss concurrent meningitis in patients presenting with tuberculomas; always perform lumbar puncture 1, 2
• Monitor for immune reconstitution inflammatory syndrome (IRIS) in HIV-positive patients starting antiretroviral therapy during TB treatment 5, 6

Neurosurgical Considerations

Refer for neurosurgical evaluation if:

• Hydrocephalus develops 1
• Tuberculous cerebral abscess is present 1
• Spinal cord compression or paraparesis occurs 1
• Progressive neurological deterioration despite medical therapy 3

Prognosis and Outcome Assessment

• Mortality in hospitalized tuberculous meningitis patients reaches 42% 7
• Nearly half of tuberculous meningitis survivors exhibit impaired cognition 8
• Disseminated TB with CNS involvement, baseline modified Barthel index ≤12, and stage 3 meningitis predict poor outcomes 9
• Treatment delay is strongly associated with death; early initiation is critical 3